Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. MAIT cell subtypes in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Antibodies to Epstein-Barr virus and neurotropic viruses in multiple sclerosis and optic neuritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. B cells from patients with multiple sclerosis have a pathogenic phenotype and increased LTα and TGFβ1 response

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MAIT cell subtypes in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Disentangling white-matter damage from physiological fibre orientation dispersion in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVE: To investigate the effect of monthly oral methylprednisolone pulse treatment in progressive MS.

METHODS: 30 progressive MS patients were treated with oral methylprednisolone every month. Peripheral blood mononuclear cells were analyzed by flow cytometry.

RESULTS: Out of 102 leukocyte phenotypes investigated, 25 changed at nominal significance from baseline to week 12 (p<0.05). After correction for multiple comparisons, we found 5 subpopulations that changed compared to baseline. No pattern were suggesting modulation of Th17 or TFH cells.

CONCLUSION: Methylprednisolone pulse treatment has some effects on circulating immune cells but does not modulate markers of Th17 and TFH cell activity in progressive MS.

Original languageEnglish
JournalJournal of Neuroimmunology
Volume276
Issue number1-2
Pages (from-to)195-201
Number of pages7
ISSN0165-5728
DOIs
Publication statusPublished - 15 Nov 2014

    Research areas

  • Adult, Anti-Inflammatory Agents, Female, Flow Cytometry, Humans, Leukocytes, Mononuclear, Male, Methylprednisolone, Middle Aged, Multiple Sclerosis, Severity of Illness Index

ID: 44920540